Personalized DNAJB1-PRKACA-derived peptide vaccine induces long-lasting DNAJB1-PRKACA-specific immune response and shows favorable clinical outcome in a FL-HCC patient. This evidence concerns the gene DNAJB1 and hepatocellular carcinoma.